C-RBFEEffePharm Ltd.
NAD+ precursors, liposomal delivery, bioactive ingredients
consumer products
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-RBFE
C-RBFEC-RBFENAD+ precursors, liposomal delivery, bioactive ingredients
0-100 chain-logic scale · 15 dimensions · scored on public evidence
EffePharm Ltd. NAD+ precursors, liposomal delivery, bioactive ingredients
EffePharm is a biotech company offering science-backed bioactive ingredients for unmet nutrition needs. Its products and technologies include UTHEVER NMN, UthPeak NMNH, LipoAvail liposomal technology, CelleSperse micelles technology, EncapCirc microencapsulation technology, and the Effe-PLUS ingredient delivery platform. The company emphasizes clinical validation, biosynthesis-driven innovation, bioavailability, stability, traceability, and scalable manufacturing for global partners.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
EffePharm Ltd. — Far from goals · Bottom quartile. Derived deterministically from 12 extracted project(s). Most-advanced status: exploratory. Band: far. Modifiers: +5 depth (5 programs at exploratory).…
Source: Deterministic